The largest holder of Jazz Pharmaceuticals stock is BlackRock Advisors LLC, with 5.5 million shares (8.52% of the company), worth about $1.39 billion as of September 25, 2026. The 10 largest holders together own 43.8%.
In Q2 2026, 673 institutional holdings reports listed shares worth $15.60 billion.
Insiders reported 85 transactions in the last two years: 35 sales worth $45.68 million and 1 purchase. The newest one on file is from May 1, 2026 (Cozadd Bruce C, Director).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 1, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Advisors LLC | 5.5 million | 8.52% | $1.4B |
| Fidelity Management & Research Co. LLC | 4.6 million | 7.10% | $1.2B |
| Vanguard Portfolio Management LLC | 3.0 million | 4.68% | $761.0M |
| Vanguard Capital Management LLC | 2.7 million | 4.21% | $684.0M |
| Capital Research & Management Co. (World Investors) | 2.7 million | 4.16% | $676.0M |
| LSV Asset Management | 2.3 million | 3.50% | $570.0M |
| Fiduciary Trust Company International | 2.0 million | 3.09% | $503.0M |
| State Street Corporation | 2.0 million | 3.08% | $501.0M |
| BNY Mellon Investment Adviser, Inc. | 1.9 million | 2.97% | $483.0M |
| DFA Australia Ltd. | 1.6 million | 2.54% | $413.0M |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 673 | – | $15.6B |
| Q1 2026 | 601 | 65.0 million | $12.3B |
| Q4 2025 | 610 | 63.4 million | $10.8B |
| Q3 2025 | 528 | 62.6 million | $8.3B |
| Q2 2025 | 522 | 62.2 million | $6.6B |
| Q1 2025 | 577 | 60.1 million | $7.5B |
| Q4 2024 | 528 | 59.3 million | $7.3B |
| Q3 2024 | 496 | 59.6 million | $6.6B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Cozadd Bruce C | May 1, 2026 | Director | Sale at price 203.33 per share. | $1.2M |
| Cozadd Bruce C | Apr 1, 2026 | Director | Sale at price 190.22 - 191.74 per share. | $1.1M |
| Carr Patricia | Mar 9, 2026 | Officer | Sale at price 182.94 per share. | $235,444 |
| Cozadd Bruce C | Mar 3, 2026 | Director | Sale at price 186.09 - 187.84 per share. | $1.1M |
| Carr Patricia | Feb 27, 2026 | Officer | Sale at price 190.91 - 194.11 per share. | $456,466 |
| Riedel Norbert G | Feb 27, 2026 | Director | Sale at price 192.00 per share. | $655,680 |
| Riedel Norbert G | Feb 27, 2026 | Director | Conversion of Exercise of derivative security at price 138.08 per share. | $471,543 |
| Henderson Mary Elizabeth | Feb 26, 2026 | Officer | Sale at price 194.49 per share. | $1.0M |
| Patil Neena M | Feb 26, 2026 | Officer | Sale at price 189.81 - 193.60 per share. | $10.7M |
| Patil Neena M | Feb 26, 2026 | Officer | Conversion of Exercise of derivative security at price 113.10 - 137.12 per share. | $6.5M |
| Love Ted Wendell | Feb 26, 2026 | Director | Stock Award(Grant) at price 0.00 per share. | – |
| Iannone Robert | Feb 26, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
Newest 12 of 85 insider transactions in the last two years.
BlackRock Advisors LLC, with 8.52% of the company (as of September 25, 2026). Next: Fidelity Management & Research Co. LLC (7.10%) and Vanguard Portfolio Management LLC (4.68%).
673 institutional holdings reports listed Jazz Pharmaceuticals shares in Q2 2026 worth $15.60 billion.
In the last two years insiders reported 35 sales and 1 purchase (85 transactions in all); the newest on file is from May 1, 2026.